[144] Beta Bionics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Beta Bionics, Inc. (BBNX) shows a proposed sale of 100 common shares through Merrill Lynch on NASDAQ with an aggregate market value of $2,100. The filing identifies the shares as acquired on 09/05/2025 by exercise of stock options from the issuer and paid in cash the same date. The filer has executed several recent open-market sales: 4,413 shares on 08/22/2025 for $75,082.65, 5,587 shares on 08/19/2025 for $95,171.78, and 1,497 shares on 06/02/2025 for $26,783.06. The notice includes the standard representation that the seller attests not to possess undisclosed material adverse information.

Positive

• Source of shares disclosed: Shares were acquired by stock option exercise, clarifying the origin of the securities
• Payment method specified: Payment was made in cash on the acquisition date
• Broker and exchange named: Sale to be executed through Merrill Lynch on NASDAQ, giving market execution clarity

Negative

• Insider selling activity: Prior open-market sales of 11,497 shares in the last three months may be viewed as increased insider liquidity
• Small remaining share count disclosed: Proposed sale is only 100 shares, suggesting limited additional disclosure value

Insights

Securities Analyst

TL;DR: Officer/insider plans a small sale after option exercise; recent larger open-market sales occurred in June-August.

The filing documents a modest proposed sale of 100 shares valued at $2,100 via Merrill Lynch on NASDAQ, arising from stock-option exercise on the same date. That contrasts with prior open-market dispositions totaling 11,497 shares across three transactions generating $197,037.49 in gross proceeds over June–August 2025. For investors, the filing is a routine insider liquidity event; it discloses source (options) and payment method (cash) and contains the required attestation about material nonpublic information.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure showing option exercise sales and recent aggregated insider selling.

The notice follows Rule 144 requirements by specifying acquisition date, nature (stock options), and that proceeds are paid in cash. It lists the broker and exchange and records prior sales by the same person in the past three months. From a governance perspective, the form contains expected certifications and a signature block warning about misstatements. No regulatory exceptions or 10b5-1 plan date are reported in the remarks section.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO Box 7297 Rancho Santa Fe CA 92067	100	2100.00	43470125	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Stock Options	Issuer			100	09/05/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Feider 11 HUGHES Irvine CA 92618	Common	08/22/2025	4413	75082.65
Stephen Feider 11 HUGHES Irvine CA 92618	Common	08/19/2025	5587	95171.78
Stephen Feider 11 HUGHES Irvine CA 92618	Common	06/02/2025	1497	26783.06

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Beta Bionics (BBNX) report?

The form reports a proposed sale of 100 common shares via Merrill Lynch on NASDAQ with an aggregate market value of $2,100.

How were the 100 shares in the Form 144 acquired?

The shares were acquired on 09/05/2025 by exercise of stock options from the issuer and paid in cash the same date.

Has the filer sold other Beta Bionics shares recently?

Yes. The filer sold 1,497 shares on 06/02/2025 for $26,783.06, 5,587 shares on 08/19/2025 for $95,171.78, and 4,413 shares on 08/22/2025 for $75,082.65.

Which broker and exchange are named for the proposed sale?

The broker is listed as Merrill Lynch (address provided) and the sale is to occur on NASDAQ.

Does the Form 144 include any 10b5-1 plan date or special remarks?

No date of a plan adoption or 10b5-1 instruction is provided in the remarks section of this filing.